SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis–Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer
Purpose: Intensification of androgen deprivation therapy (ADT) with either docetaxel or
androgen receptor axis–targeted therapies (ARAT) are the current standard of care for …
androgen receptor axis–targeted therapies (ARAT) are the current standard of care for …
[HTML][HTML] Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer
M Rijnders, JA Nakauma-González… - Nature …, 2024 - nature.com
Immune checkpoint inhibitors (ICI) improve overall survival in patients with metastatic
urothelial cancer (mUC), but therapeutic success at the individual patient level varies …
urothelial cancer (mUC), but therapeutic success at the individual patient level varies …
[HTML][HTML] Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis
RSP Huang, DP Carbone, G Li, A Schrock… - … for ImmunoTherapy of …, 2023 - ncbi.nlm.nih.gov
Background For patients with advanced non-small cell lung carcinoma (NSCLC), immune
checkpoint inhibitor (ICPI) and chemotherapy (chemo) ICPI represent two distinct first-line …
checkpoint inhibitor (ICPI) and chemotherapy (chemo) ICPI represent two distinct first-line …
[HTML][HTML] Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling–informed …
T Powles, A Young, H Nimeiri, RW Madison… - Frontiers in …, 2023 - frontiersin.org
Introduction Circulating tumor DNA (ctDNA) detection postoperatively may identify patients
with urothelial cancer at a high risk of relapse. Pragmatic tools building off clinical tumor next …
with urothelial cancer at a high risk of relapse. Pragmatic tools building off clinical tumor next …
T Cell-to-Stroma Enrichment (TSE) score: a gene expression metric that predicts response to immune checkpoint inhibitors in patients with urothelial cancer
M Rijnders, JA Nakauma-González, DGJ Robbrecht… - bioRxiv, 2022 - biorxiv.org
Immune checkpoint inhibitors (ICIs) improve overall survival in patients with metastatic
urothelial cancer (mUC). To identify predictive markers of response, whole-genome DNA (n …
urothelial cancer (mUC). To identify predictive markers of response, whole-genome DNA (n …